Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ

使用下一代 DNA 序列治疗高胆固醇血症的新方法

• 批准号: 8645955
• 负责人: Richard August Shimkets
• 金额: $ 24.21万
• 依托单位: ABEOME CORPORATION
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-02-12 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8645955
• 关键词: Affinity; Animals; Antibodies; Antibody Affinity; Antibody Repertoire; Antibody-Producing Cells; Antigens; B-Lymphocytes; Binding; Biological Assay; Biotechnology; Businesses; Cells; Characteristics; Clinical; Clinical Trials; DNA; DNA Sequence; Data; Diagnostic; Drug Targeting; Escherichia coli; Generations; Genes; Goals; Harvest; Hepatocyte; Human; Hybridomas; IL6 gene; Immune system; Injection of therapeutic agent; Label; Legal patent; Libraries; Light; Low-Density Lipoproteins; Lymphoid Tissue; Marketing; Methods; Monoclonal Antibodies; Mus; Ovalbumin; Pharmacologic Substance; Phase; Property; Proteins; Publishing; Recombinants; Sales; Services; Speed; Surface; Surface Plasmon Resonance; System; Technology; Testing; Therapeutic; Transgenic Mice; Transgenic Organisms; base; hypercholesterolemia; instrument; mouse model; neutralizing antibody; next generation; novel; novel therapeutic intervention; public health relevance; response; screening; uptake

DESCRIPTION (provided by applicant): We have developed and completed a proof-of-principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to ovalbumin injection using surface antibody capture and next-generation DNA sequencing technologies. A more commercially valuable proof is now sought using a novel screening method with an emerging drug target for hypercholesterolemia, known as PCSK9.

描述（由申请人提供）：我们已经开发并完成了一种新的转基因小鼠模型的原理验证，该模型用于使用表面抗体捕获和下一代DNA测序技术对响应于卵清蛋白注射的抗体库进行全面表征。现在使用一种新的筛选方法寻找更具商业价值的证据，该方法具有高胆固醇血症的新兴药物靶点，称为PCSK 9。